1. Home
  2. CCG vs TCRX Comparison

CCG vs TCRX Comparison

Compare CCG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCG

Cheche Group Inc.

N/A

Current Price

$0.98

Market Cap

81.1M

Sector

N/A

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.03

Market Cap

64.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCG
TCRX
Founded
2014
2018
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.1M
64.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CCG
TCRX
Price
$0.98
$1.03
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$350.00
$8.50
AVG Volume (30 Days)
78.1K
823.7K
Earning Date
11-26-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$444,290,042.00
$8,423,000.00
Revenue This Year
N/A
$286.83
Revenue Next Year
$15.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.91
52 Week High
$1.54
$3.43

Technical Indicators

Market Signals
Indicator
CCG
TCRX
Relative Strength Index (RSI) 45.21 39.94
Support Level $0.93 $0.99
Resistance Level $1.00 $1.09
Average True Range (ATR) 0.05 0.09
MACD 0.00 0.03
Stochastic Oscillator 41.67 35.71

Price Performance

Historical Comparison
CCG
TCRX

About CCG Cheche Group Inc.

Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: